Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Persons with chronic pain and women tend to enter treatment for opioid use disorder with greater opioid withdrawal severity than persons without chronic pain and men, respectively. This study examined characteristics of facilities with opioid withdrawal treatment, including gender-based services, as a function of whether they reported having a tailored pain management program.
Methods: The National Survey of Substance Abuse Treatment Services 2020 was used to examine 3942 facilities with opioid withdrawal treatment in the United States. Using a multivariable binary logistic regression model, facilities were examined for the presence of a tailored program for individuals with co-occurring pain. Regional location of the facility, ownership status, and availability of tailored gender programs, nonhospital residential services, and outpatient services served as independent variables in the analysis.
Results: A slight majority of the sample had a program for both adult men and adult women ( n = 2010, 51.0%). Most facilities had outpatient services ( n = 3289, 83.4%) and did not have a tailored program for addressing co-occurring pain ( n = 2756, 69.9%). Binary logistic regression analysis showed that among opioid withdrawal facilities, programs with nonhospital residential services, government or private nonprofit funding, or tailored gender programming had higher odds of reporting having a tailored program for pain and substance use disorder. Facilities in the Western United States were most likely to have tailored programs for pain and substance use disorder.
Conclusions: Future research should investigate what support patients may receive and how to better scale access to pain management during opioid withdrawal treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ADM.0000000000001278 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-Effectiveness of Treatment for Opioid Use Disorder in Pregnancy and Its Impact on Birth Outcomes.
JAMA Pediatr
September 2025
Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Importance: For the first time in nearly 2 decades, the US infant mortality rate has increased, coinciding with a rise in overdose-related deaths as a leading cause of pregnancy-associated mortality in some states. Prematurity and low birth weight-often linked to opioid use in pregnancy-are major contributors.
Objective: To assess the health and economic impact of perinatal opioid use disorder (OUD) treatment on maternal and postpartum health, infant health in the first year of life, and infant long-term health.
Opioid agonist therapy for opioid use disorder in primary versus specialty care.
Cochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDFTreatment and Referral of Youth with Opioid Addiction in the Pediatric Emergency Department: A Pilot Study.
Acad Pediatr
September 2025
Division of Emergency and Transport Medicine, Children's Hospital Los Angeles, Los Angeles, California; Department of Pediatrics, Keck School of Medicine of the University of Southern California, Los Angeles, California. Electronic address:
Background: Fatal opioid overdoses have increased among adolescents. Emergency Departments (EDs) are critical access points for connecting adults with opioid use disorder (OUD) to medication-assisted treatment (MAT). Whether this is feasible in pediatric patients is unknown.
View Article and Find Full Text PDFBiasing G protein βγ subunit downstream signaling enhances the analgesic effects of endogenous opioid receptor agonists during nitroglycerin-induced thermal hypersensitivity.
Mol Pharmacol
August 2025
Department of Pharmacology, University of Michigan, Ann Arbor, Michigan.
μ-Opioid receptor (MOR) agonists are a mainstay in acute pain management. However, they also produce adverse effects and are frequently misused, increasing susceptibility for opioid use disorder. Thus, a strategy for improving the safety of opioid analgesics is needed.
View Article and Find Full Text PDFEffects of Naltrexone on Gabapentin Reward and Buprenorphine Combinations in Male Mice.
Behav Brain Res
September 2025
Department of Psychological Science, Northern Michigan University.
Gabapentin (GBP), an anticonvulsant approved for seizures and neuropathic pain, is frequently co-prescribed with buprenorphine (BUP), a partial mu-opioid receptor (MOR) agonist, to manage withdrawal and pain in individuals with opioid use disorder (OUD). While GBP is generally considered safe, emerging evidence suggests abuse potential when combined with opioids. This study used the conditioned place preference (CPP) paradigm to assess the rewarding effects of GBP alone and in combination with BUP.
View Article and Find Full Text PDF